In a publication written by scientists, Sun et al. 2021, from the CAS Key Laboratory of Pathogenic Microbiology and Immunology at the Chinese Academy of Sciences, endeavored to develop a broad-spectrum multivalent vaccine to combat rapidly emerging variants of SARS-CoV-2. Their approach involved the production of lipid nanoparticle-based trimeric receptor binding domain (RBD) mRNA vaccines using the NanoAssemblr ® microfluidic mixing platform. The formulation showcased strong immune responses in HACE2-transduced mice that were challenged with SARS-Cov-2. The mRNA payload encoded for the trimeric RBD of the SARS-CoV-2 spike (S) protein and the protein ferritin (TF-RBD) which was then encapsulated by lipid nanoparticle formulations. Aside from the TF-RBD vaccine’s ability to induce robust and durable humoral immunity, several pseudoviral assays applied to immunized mice reveal broad spectrum immunity through higher levels of cross-neutralizing antibody responses against the Alpha, as well as Beta variants of SARS-CoV-2. The versatility and fast engineering approach in developing mRNA payloads to incorporate vaccine adjuvants like ferritin as exemplified in this paper can pave the way for further advancements in nanoparticle subunit vaccines that may play a key role in addressing new viral variants of arising infectious diseases.